Cytek Biosciences Financial Ratios
NASDAQ: CTKBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
5.43+0.07 (+1.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytek Biosciences ratio analysis
Cytek Biosciences earned a net margin of -33.0% in FY 2025, down from -3.0% a year earlier. Gross margin was 51.8% compared with a median of 3407.8% over the prior 5 years. Return on equity reached -19.5%, meaning Cytek Biosciences generated -0.19 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Cytek Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 510.50 | — | — |
| Price / sales | 3.12 | 4.45 | 6.39 | 463.50 | 574.24 | — |
| Price / book | 1.84 | 2.25 | 3.14 | 3.23 | 3.09 | — |
| Gross margin | 51.8% | 55.4% | 56.7% | 3,407.8% | 3,628.8% | 7,283.1% |
| Operating margin | -20.0% | -10.2% | -14.4% | -60.9% | 419.9% | 1,923.8% |
| Net margin | -33.0% | -3.0% | -6.3% | 83.8% | 138.8% | 2,733.9% |
| Free cash flow margin | -4.4% | 10.9% | 0.3% | -741.8% | 12.2% | 1,916.8% |
| Return on equity (ROE) | -19.5% | -1.5% | -3.1% | 0.6% | 0.7% | — |
| Return on assets (ROA) | -14.4% | -1.2% | -2.5% | 0.5% | 0.7% | 8.8% |
| Current ratio | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 | 7.86 |
| Revenue growth | 0.5% | 3.9% | 6,414.2% | 35.9% | 207.2% | — |
| EPS growth | — | — | -550.0% | — | -100.0% | — |